4/A: Olema Pharmaceuticals Director Amends SEC Filing After Incorrectly Reporting Transaction Date

A director of Olema Pharmaceuticals, Graham Walmsley, has amended a previous SEC filing to correct the date of a stock transaction.

Summary

• Graham Walmsley, a director at Olema Pharmaceuticals, filed an amendment to a previous SEC Form 4.
• The amendment corrects the date of the earliest transaction reported, changing it from September 12, 2023, to June 4, 2024.
• The original filing incorrectly stated the transaction date, but all other information in the original filing remains unchanged.
• On June 4, 2024, Walmsley sold 700,000 shares of common stock at $14.85 per share.
• Also on June 4, 2024, Walmsley sold 475,000 shares of common stock at $14.85 per share.
• The shares are indirectly held through Logos Opportunities Fund I LP and Logos Opportunities Fund II LP, where Walmsley is a managing member of the general partner.

Sentiment

Score: 5

Explanation: The document is a routine correction of a filing, not indicative of positive or negative sentiment. The large sale of shares is a neutral event as it is not clear why the shares were sold.

Risks

• The need for an amendment indicates a potential for errors in reporting, which could raise concerns about internal controls.
• Large sales of shares by a director could be interpreted negatively by the market.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in the pharmaceutical industry. It is important for investors to monitor these filings to understand the actions of company insiders.

Comparison to Industry Standards

• SEC Form 4 filings are a standard requirement for company insiders, such as directors, who trade in their company's stock.
• The level of detail and the requirement to disclose transactions are consistent with industry standards for transparency and regulatory compliance.
• The amendment highlights the importance of accuracy in these filings, which is a common issue across all industries.

Stakeholder Impact

• The amendment ensures transparency for shareholders regarding insider transactions.
• The sale of shares by a director could potentially impact investor confidence, depending on market interpretation.

Key Dates

Keywords

SEC Form 4, amendment, stock transaction, Graham Walmsley, Olema Pharmaceuticals, insider trading, share sale, beneficial ownership